-
All Events
ESOT DCD CongressWorkshopESOT ELITA -
All Content TypesAbstractAccredited ActivityAccredited CourseArticle ReviewAudio PodcastCase StudyClinical CaseCurriculumDocumentDocumente-Booke-SeriesePosterExternal LectureIndexed SlideJournal ArticleLearning QuizLive StreamMatching SlidePPT SharedSelf-Test CaseTechnical VideoVideo SessionWebcast
-
Sort ByRelevanceMost RecentAlphabetical OrderHighest ContributorsOldest
Around 25% of organ transplant recipients encounter acute rejection within the initial year post-transplantation. Acute rejection is further categorized into cellular (ACR) and antibody-mediated (AMR) forms. Over the long term, the threat shifts to chronic rejection, posing a risk to patient survival even with immunosuppressive drug treatments. Factors such as opportunistic viral infections and malignancies contribute to this risk. Consequently, there is a keen interest in therapies that can effectively modulate the immune system, presenting promising avenues for treating and preventing rejection in transplant recipients.
This workshop will address the patient experience of immunomodulation and rejection. How the patients and their family experience and feel about rejection.
Target Audience:
Patients, Caregivers, Patient Advocates, Representatives of Patient Associations and Organizations
Workshop creators:
Markus Johannes Barten (Germany)
Julie Guest (UK)
Invited speakers and moderators:
Francis Ayuketang Ayuk (Germany)
Markus Johannes Barten (Germany)
Charlotte Davies (UK)
Pisana Ferrari (Italy)
Julie Guest (UK)
Marc Kritzky (Germany)
After attending this online workshop participants will learn:
• The difference between cellular and antibody-mediated acute rejection
• The characteristics and the risks associated with chronic rejection
• The difference between immunosuppression and immunomodulation
• The step-by-step process of inducing immunomodulation, from the mechanism of action to its implementation in a healthcare facility
• To assess the safety aspects of immunomodulation in the context of organ transplantation
University Heart § Vascular Center, University Medical Hospital Hamburg, Dep. of Cardiovascular Surgery
Around 25% of organ transplant recipients encounter acute rejection within the initial year post-transplantation. Acute rejection is further categorized into cellular (ACR) and antibody-mediated (AMR) forms. Over the long term, the threat shifts to chronic rejection, posing a risk to patient survival even with immunosuppressive drug treatments. Factors such as opportunistic viral infections and malignancies contribute to this risk. Consequently, there is a keen interest in therapies that can effectively modulate the immune system, presenting promising avenues for treating and preventing rejection in transplant recipients.
This workshop will address the patient experience of immunomodulation and rejection. How the patients and their family experience and feel about rejection.
Target Audience:
Patients, Caregivers, Patient Advocates, Representatives of Patient Associations and Organizations
Workshop creators:
Markus Johannes Barten (Germany)
Julie Guest (UK)
Invited speakers and moderators:
Francis Ayuketang Ayuk (Germany)
Markus Johannes Barten (Germany)
Charlotte Davies (UK)
Pisana Ferrari (Italy)
Julie Guest (UK)
Marc Kritzky (Germany)
After attending this online workshop participants will learn:
• The difference between cellular and antibody-mediated acute rejection
• The characteristics and the risks associated with chronic rejection
• The difference between immunosuppression and immunomodulation
• The step-by-step process of inducing immunomodulation, from the mechanism of action to its implementation in a healthcare facility
• To assess the safety aspects of immunomodulation in the context of organ transplantation
